Duke CTSA KL2 News

Duke CTSI is pleased to present the 2023 CTSI Translational Impact Report, Partnering to Improve Health, Trust, and Equity in our Communities.

As a recipient of the Duke Clinical and Translational Science Award (CTSA) KL2 career development award, Michael Paul Cary, PhD, RN, FAAN, exemplifies the type of researcher who best benefits from the unique program that supports early-stage translational investigators.

The Duke CTSA KL2 Symposium featured presentations from the graduating KL2 scholars and personal thoughts about each scholar from their primary mentors. 

Kimberly Johnson, MD, director of the Duke CTSA KL2 Program, presented her research on equity in serious illness care for African Americans during the final installment of Duke School of Medicine’s Dean’s Distinguished Research Series.

The 8^th annual Duke CTSA KL2 symposium was held on Tuesday, June 14.  A virtual event since 2020, the symposium features presentations from the graduating KL2 scholars and congratulations and personal thoughts about each scholar from the primary mentors. This year, four KL2 scholars are exiting the program after successfully completing the program: 

 

The Duke CTSA KL2 program provides training opportunities and protected research effort for junior investigators. KL2 scholars will leave the program equipped with the skills to be successful, independent investigators, making contributions across the spectrum of clinical and translational science.

Rasheed Gbadegesin, MD, has been named Associate Dean for Physician-Scientist Development and Director of the Office of Physician-Scientist Development (OPSD), a school-wide initiative focused on the training and support of physician-scientists. Dr. Gbadegesin has served as the inaugural faculty director of OPSD since 2018.

Duke CTSA KL2 Scholar Carlene Moore, PhD, recently appeared on a list of 1,000 inspiring black scientists in the U.S. Dr. Moore was one of 13 Duke scientists on the list, published by Cell Mentor, an online resource and blog for researchers.

Dr. Moore joined the Duke KL2 program in 2018 as a member of the sixth cohort. Her research focuses on the role that TRPV4 ion channels play in the conduction and perception of pain.

The Duke CTSA KL2 program was recently identified as one of the top program hubs by the Center for Leading Innovation and Collaboration (CLIC). The Duke KL2 program was a top performer in the KL2 education program – Underrepresented measure.

The Duke CTSA KL2 program provides training opportunities and protected research effort for junior investigators. KL2 scholars will leave the 3-year program equipped with the skills to be successful, independent investigators, making contributions across the spectrum of clinical and translational science. This year, two new investigators will join the program: Joshua Thaden, MD, PhD; and Michelle White, MD, MPH.